Analysts' Opinions on Sarepta

Order byBest matchMost fresh

Sarepta reports Third patient death

Sarepta tells FDA it won’t halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient r...

· 1d

Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies

· 12h

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths

· 1d

FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy

A 51-year-old man died last month after receiving an experimental gene therapy developed by Sarepta Therapeutics for an ultra-rare form of muscular dystrophy, a company spokesperson confirmed Thursda...

· 1d

Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says

· 1d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

Fierce Biotech1d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

BioSpace2d

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant pipeline shift and adding a black box warning to its Duchenne muscular dystrophy gene therapy Elevidys.

TipRanks on MSN16h

JPMorgan, Starbucks, HPE, Sarepta, Elevance: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent

Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm downgrading SRPT stock from Hold to Sell.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Asianet Newsable on MSN1d

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.

1don MSN

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for one of its medications.

Sarepta: Finally, A Little Relief For Bulls; I Expect More

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an investment analysis.

Nasdaq1y

12 Analysts Have This To Say About Sarepta Therapeutics

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...